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Abstract: The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor
entities. However, the lack of inhibitors crossing the blood–brain barrier remains a significant obstacle
for clinical translation. Here, we targeted the IGF pathway using ceritinib, an off-target inhibitor of
the IGF1 receptor (IGF1R) and insulin receptor (INSR), in a pediatric patient with an unclassified
brain tumor and a notch receptor 1 (NOTCH1) germline mutation. Pathway analysis of the tumor
revealed activation of the sonic hedgehog (SHH), the wingless and integrated-1 (WNT), the IGF,
and the Notch pathway. The proliferation of the patient tumor cells (225ZL) was inhibited by arsenic
trioxide (ATO), which is an inhibitor of the SHH pathway, by linsitinib, which is an inhibitor of IGF1R
and INSR, and by ceritinib. 225ZL expressed INSR but not IGF1R at the protein level, and ceritinib
blocked the phosphorylation of INSR. Our first personalized treatment included ATO, but because
of side effects, we switched to ceritinib. After 46 days, we achieved a concentration of 1.70 µM of
ceritinib in the plasma, and after 58 days, MRI confirmed that there was a response to the treatment.
Ceritinib accumulated in the tumor at a concentration of 2.72 µM. Our data suggest ceritinib as a
promising drug for the treatment of IGF-driven brain tumors.
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1. Introduction
Brain tumors are the most common solid tumors and a leading cause of cancer-related death in
children. The advances in molecular biology have identified critical cellular changes within pediatric
brain tumors, suggesting that molecularly targeted therapy may improve the treatment of these patients.
The insulin-like growth factor (IGF) pathway has long been recognized for its role in tumorigenesis
and growth. The IGF axis includes three ligands (IGF1, IGF2, and insulin) and two homolog receptors,
insulin like growth factor 1 receptor (IGF1R) and insulin receptor (INSR; for a review, see [1]). In the
brain, IGF1R, IGF1, and IGF2 are highly expressed during embryonic and early postnatal development,
and decrease substantially during adolescence [2]. In brain tumors, the IGF axis is frequently activated
in medulloblastoma [3,4] glioblastoma [5], and ependymoma [6]. Several strategies have been tested
to interfere with IGF signaling, including IGF1R blockade by monoclonal antibodies, small molecule
tyrosine kinase inhibitors of IGF1R and INSR, and ligand neutralizing strategies [7], but so far, there
are no US Food and Drug Administration (FDA)-approved drugs available. Thus, drug repositioning
i.e., the strategy of using existing drugs originally developed for one disease to treat other indications,
may represent a way forward to rapid clinical use.
Ceritinib gained US Food and Drug Administration approval in 2014 for the treatment of patients
with ALK-positive metastatic non-small-cell lung cancer (NSCLC) who have progressed on or are
intolerant to crizotinib [8]. Ceritinib can also inhibit INSR and IGF1R [9], suggesting a potential role
in the development of therapy protocols targeting the IGF axis. Ceritinib indeed has been used to
successfully inhibit IGF1R phosphorylation in models of rhabdomyosarcoma [10] and of high-grade
neuroepithelial tumor with BCOR alteration (HGNET-BCOR) [11].
Here, we targeted the IGF pathway in a pediatric patient with a neuroepithelial tumor that was
neuropathologically classified as an anaplastic ependymoma, but could not be assigned to a defined
DNA-methylation class of brain tumors. Our in vitro and in vivo data indicate that ceritinib can be
used to target INSR, and that ceritinib penetrates the human blood–brain barrier (BBB).
2. Results
2.1. Clinical Description
A 4-year-old female patient without any relevant prior medical condition was transferred to our
center after the gross total microsurgical resection of a 5.1 × 3.6 × 2.1 cm hemorrhagic tumor in the
right parieto-occipital lobe. The postoperative staging scans revealed no metastases. The tumor was
classified as an anaplastic ependymoma (WHO III), and the patient received focal irradiation according
to the international HIT-MED registry (Version 1.0, 12 January 2014). Five months after cessation of
radiotherapy, a first metastatic relapse occurred in the temporofrontal region. Gross total microsurgical
resection of the first metastasis was performed, and we initiated systemic chemotherapy based on
cycles of cyclophosphamide/vincristine and carboplatin/etoposide according to the HIT-MED Guidance
(Ependymoma, M0, R0, 4–21 years and protocol version 3.0, 16th September 2015). Four months later,
the patient developed a second metastasis/metachronous tumor in the temporomesial region, and we
decided to switch to a personalized treatment based on the molecular analysis of the tumor.
2.2. Histopathology
The histopathological report of the primary tumor was suggestive of a small, round, blue cell tumor
with co-expression of neuronal antigens (NeuN and CD56) and epithelial antigens (EMA) (Figure 1B–D).
Ki67 staining was indicative of more than 10% proliferating tumor cells (Figure 1E). Further central
reference pathological review and additional molecular evaluation (RT-PCR and sequencing) led to the
Int. J. Mol. Sci. 2019, 20, 4267 3 of 19
diagnosis of an anaplastic ependymoma (WHO III) carrying a C11orf95-RELA fusion. However, L1Cam,
a surrogate marker for RELA fusion-gene positivity, was detected only in a subfraction of tumor cells
(Figure 1F). Moreover, in this specimen, subpopulations of cells showed nuclear accumulation of the
p65RelA protein as specific indication of NFκB activation [12] (not shown). The tumor protein P53
(TP53) gene product was accumulated in approximately 20% of cells. Histology of the first metastatic
relapse revealed a tumor lacking any characteristic patterns (Figure S1). The tumor cells were round
to oval and of varying size, with only a scant cytoplasm. Sometimes, distinct nucleoli were present.
Mitotic activity was brisk. There was geographic necrosis. Immunohistochemically, most tumor cells
were positive for EMA, while some displayed positivity for L1Cam. P53 accumulation was present in
the majority of cells Nuclear INI1-positivity was retained (Figure S1). The tumor was negative for glial
fibrillary acidic protein (GFAP) and isocitrate dehydrogenase (NADP(+)) 1 (IDH1) R132H (Figure S1).
The Ki67 proliferation index was up to about 50%. Interestingly, the C11orf95-RELA fusion could not
be detected, and the tumor cells did not show nuclear accumulation of p65RelA protein.
Figure 1. Histopathological features of the primary tumor. (A) HE staining showing small, round,
blue tumor cells. (B) Epithelial antigens (EMA). (C) NeuN. (D) CD56. (E) Ki67. (F) L1Cam. Original
magnification 200×.
2.3. Methylation Analysis Reveals a not Classifiable Tumor Entity
Due to the unexpected loss of the C11orf95-RELA fusion gene, we analyzed the primary tumor
and the first metastatic relapse by 850k DNA methylation bead array analysis and the brain tumor
classification tool recently described by Capper et al. (classifier version v11b4) [13]. The DNA
methylation signatures of the primary tumor (no. 176), the metastasis (no. 225), and of the primary
tumor cells isolated from the metastasis and grown in vitro (no. 225 ZL) did not show similarities with
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any known brain tumor DNA methylation class defined in this classifier version (Table 1), and thus
were not classifiable by this method. A principal component analysis of genes conducted with the
R package “RnBeads” indicated that the three samples cluster together, but not with C11orf95-RELA
fusion gene positive ependymoma samples (Figure 2). These results argue for intermethodological
discrepancies in the primary tumor, as RT-PCR and sequencing detected a C11orf95-RELA fusion gene,
although 850k DNA methylation analysis did not show an association with the DNA methylation class
of the C11orf95-RELA fusion gene positive ependymoma.
Table 1. Results of the methylation classifier and summary of the chromosomal aberrations.
Sample Type Sample ID MethylationClassifier‘Result Chromosomal Aberrations
Primary tumor 176 unclassified Gain on chromosome 2 and 11q
First metastatic relapse 225 unclassified
Tendency to gain on chromosomes 1p, 2,
7q partially, 11q, 21q;
loss of chromosomes 17p, 19p
in vitro culture of
tumor cells 225 ZL unclassified
Gain on chromosomes 1p, 2, 7q partially,
11q, 21q;
loss of chromosomes 17p, 18q, 19p
Figure 2. Principal Component Analysis. Principal component analysis by genes based on 850 k DNA
methylation analysis for different tumor entities commonly found in childhood. Samples of the index
patient do not cluster together with ependymoma, RELA fusion-positive tumors (arrow heads), but
rather form their own cluster (arrows). The kind of material used for the analysis is indicated (fresh
frozen or formalin-fixed, paraffin-embedded (FFPE)).
The copy number profile derived from the DNA methylation array data revealed a gain of
chromosome 2 and chromosome 11q in the primary tumor (Table 1 and Figure S2). The first metastatic
relapse further showed gains of chromosomes 1p, partially of 7q and 21q, and losses of chromosomes
17p and 19p. The copy number profiles of primary tumor cells showed an additional loss of
chromosome 18q.
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2.4. Whole-Transcriptome Sequencing Reveals the Activation of Several Embryonic Pathways
To identify therapeutic targets, whole-transcriptome sequencing (RNAseq) was performed using
fresh frozen tissue from the first metastatic relapse (no. 225) and normal tissue derived from normal
parietal brain (no. 111). To identify only strongly deregulated pathways, we first calculated the
ratio of the expression between the tumor tissues and the normal tissue, and selected the genes
with a fold change >10. This data set was functionally analyzed using the ‘core analysis’ of IPA.
The activated pathways are shown in Table 2. The Notch and basal cell carcinoma (BCC) pathways had
the lowest p value (p = 0.00024 and p = 0.0028, respectively). The BCC pathway is characterized by a
cross-talk between the sonic hedgehog (SHH) and the wingless and integrated-1 (WNT) signaling [14].
Deregulated genes of the Notch and BBC pathways are listed in Table S1 and Table S2, respectively.
Other pathways activated in the relapse included the G12 subfamily (Gα12/13)-mediated signaling
pathway [15] >(p = 0.0074). Since the first diagnosis of the tumor was of an ependymoma and IGF has
been recently identified as relevant target in this entity [16], we also searched the transcriptome data
for the expression of components of the IGF pathway. We observed a very strong expression of IGF2,
but not of IGF1 (Table S3). In line with the results of the reference pathology, we were not able to detect
a C11orf95-RELA fusion in the RNAseq data. However, we detected other fusions (Table 3), involving
nuclear receptor coactivator 1 (NCOA1) and GRB interacting GYF Protein 2 (GIGYF2) (both on chr.2) and
NCOA1 (chr.2) and C11orf95 (chr.11). Fusions between C11orf95 and NCOA1, a steroid receptor, have
been described in a C11orf95-RELA negative supratentorial anaplastic ependymoma [17], but their
biological significance is unknown so far. Two fusions contained intronic sequences, and are probably
not functionally relevant. One fusion contained exon 8 of GIGYF2, which is a gene that is involved in
the regulation of the IGF signaling [18]. Whether the disruption of the GIGYF2 locus has an effect on
the activation of the IGF signaling in this patient remains to be elucidated.
Table 2. Pathways activated in the first metastatic relapse. The -log of p-value (calculated by Fisher’s
exact test right-tailed) is indicated. Only pathways with a -log of p-value of more than 2 are shown.
Ingenuity Canonical Pathways -Log (p-value)
Notch Signaling 3.62
Basal Cell Carcinoma Signaling 2.55
Gα12/13 Signaling 2.13
Table 3. Fusion transcripts detected by RNA Seq.
Transcript 1 Chr Position Transcript 2 Chr Position
NCOA1 intron7 2 24914529–24916118 GIGYF2 exon8 2 233626104–233626145
NCOA1 intron12 2 24933980–24949455 GIGYF2 intron8 2 233626146–233651857
NCOA1 intron12 2 24933980–24949455 C11orf95 intron3 11 63532726–63533276
We further validated the RNAseq results by qRT-PCR using GLI family zinc finger 2 (GLI2), AXIN2,
and hes family bHLH transcription factor 4 (HES4) as surrogate markers for the activation of the SHH,
WNT, and Notch pathways, respectively. A strong upregulation of GLI2, AXIN2, and HES4 was detected
in the relapse compared to the two normal brain regions (Figure 3A–C). High expression of IGF2
was also detectable in the relapse material by qRT-PCR (Figure 3D). In conclusion, the transcriptome
analysis indicated a co-activation of several pathways known to play an important role in the tumor
progression and embryogenesis.
Int. J. Mol. Sci. 2019, 20, 4267 6 of 19
Figure 3. Embryonal pathways are activated in the tumor relapse. GLI family zinc finger 2 (GLI2)
(A), AXIN2 (B), hes family bHLH transcription factor 4 (HES4) (C) and insulin-like growth factor 2 (IGF2)
(D) expression was analyzed by qRT-PCR in the relapse (no 225), the primary tumor cells isolated
from the relapse (no 225ZL), and two normal brain regions (no 110, 111). After normalization to the
housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT1), the relative quantification value
was expressed as 2-∆∆Ct. The qPCR experiments were carried out in biological triplicates. Data are
represented as the mean ± standard deviation (SD). Statistical analyses were performed using t-tests
compared with sample 111 (* p < 0.01, *** p < 0.001, **** p < 0.0001).
2.5. Detection of a NOTCH 1 Germline Mutation
Due to the activation of the Notch signaling pathway, we searched for mutations in related genes in
the RNAseq data, and detected a mutation in exon 3 of notch receptor 1 (NOTCH1) (NM_017617.3:c.689G
> A). Validation by Sanger sequencing indicated that the mutation was present not only in the tumor,
but also in the lymphocytes of the patient (Figure 4A). The mutation is localized at the N terminus
of NOTCH1 (NP_060087.3:p.Gly230Glu) in the fourth EGF-like domain according to cBioPortal [19]
(Figure 4B), and is predicted to be damaging, according to polyphene [20]. A somatic mutation at this
position has been described previously in a basal cell carcinoma patient [21]. In the DNA of the tumor, but
not of the blood, a TP53 homozygous mutation was also detected (NM_000546.5:c.742C > T, rs121912651)
(Figure 4C). This mutation is localized in the DNA binding domain (NP_000537.3:p.Arg248Trp), and is
predicted to be pathogenic according to ClinVar [22]. No mutations in ALK were detected by Sanger
sequencing with primers covering the kinase domain [23].
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Figure 4. Detection of a notch receptor 1 (NOTCH1) germline mutation and a tumor protein P53 (TP53)
somatic mutation. Sanger sequencing of the genomic DNA extracted from the blood and the relapse
(no 225) was done with primers specific for the NOTCH1 (A) and the TP53 (C) mutation identified by
RNA-seq. The arrow indicates the (NM_017617.3:c.689G > A) mutation rs121912651. The arrowhead
indicates the rs121912651. (B) Structure of NOTCH1 as reported in cBioportal. The position of the
Gly230Glu mutation is indicated. Green: EGF-like domains; Red: Calcium-binding EGF domains;
Yellow: LNR Domain; Purple: NOD (NOTCH protein domain); Orange: NODP (NOTCH protein
domain); Rose: Ankyrin repeats; Dark red: unknown function.
2.6. The Primary Tumor Cells are Sensitive to Inhibition with ATO and Ceritinib
The transcriptome analysis revealed the SHH, WNT, Notch, and IGF pathways as putative targets
for a personalized therapy protocol. We selected the pathways to treat based on the biological relevance
of the pathways, safety concerns, and the availability of FDA-released drugs. To date, there is no
approved Notch and WNT targeted therapy in the clinic, and the development of life-threatening
toxicities associated with the targeting of these pathways still remain a concern [24,25]. The SHH
pathway can be targeted using vismodegib, which is an inhibitor of smoothened (SMO) that has been
approved for the treatment of the BCC [26], and ATO, an inhibitor of GLI2 [27,28]. The administration of
ATO is well established in the treatment schedule of pediatric acute promyelocytic leukemia (APL) [29].
No inhibitors for IGF1R have been released so far, but it is known from clinical studies that the
inhibition of the IGF pathway has an acceptable safety profile [30]. Moreover, ceritinib, which is
approved for anaplastic lymphoma kinase (ALK) positive lung cancer, can also inhibit IGF1R and
INSR [9]. We previously showed that ceritinib can inhibit the IGF receptor IGF1R in a particular
subtype of pediatric brain tumors at a concentration that is achievable in vivo [11]. To evaluate if the
targeting of the SHH and the IGF1R pathway could affect the growth of the tumor and to prioritize
related drugs, we tested the effect of relevant drugs on the tumor cells (225ZL) isolated from the
first relapse of the patient. We first analyzed to what extent the 225ZL cells constituted the tumor of
origin. By DNA methylation analysis, the primary tumor cells were not assigned to any known brain
tumor DNA methylation profile, but clustered together with the tumor of origin (Table 1 and Figure 2).
Chromosomal aberrations were similar to the first metastasis with an additive loss of chromosome 18q
(Table 1 and Figure S2). The Notch, SHH, and WNT pathways were active, as shown by qRT-PCR
analysis of the target genes (Figure 3A–C). IGF2 was highly expressed (Figure 3D). Then, we treated
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the 225ZL cells with ATO, vismodegib, and linsitinib, a specific but not FDA-approved inhibitor of
IGF1R and INSR [31], and ceritinib. While vismodegib at a concentration of 10 µM reduced the cell
proliferation to about 85% of the control, ATO, linsitinib, and ceritinib (all at the concentration of 1
µM) reduced the cell proliferation to about 16%, 20%, and 30% of the control respectively, after 15
days (Figure 5A). Notably, we selected the 1-µM concentration of ceritinib and linsitinib, because this
concentration can be achieved in the plasma of patients [8,32], and is therefore clinically relevant. To
identify the molecular target of ceritinib, we analyzed the expression of IGF1R and INSR by Western
blot (Figure 5B). Only INSR was expressed by the 225ZL cells. Stimulation with IGF2 induced INSR
phosphorylation in starved cells (Figure 5B, lane 2). The phosphorylation could be blocked using
ceritinib (Figure 5B, lane 3). These data indicate that GLI2 and INSR are relevant targets to be addressed
in a personalized therapy protocol, and that ceritinib can be used to target the IGF pathway.
Figure 5. The primary tumor cells are sensitive to arsenic trioxide (ATO) and ceritinib. (A) 225ZL cells
were grown for 15 days in the presence of ATO, vismodegib, linsitinib, or ceritinib. As control, the vehicle
alone was used. The percentage of the growth compared to the control is shown. The proliferation
experiments were carried out in biological duplicates. Data are represented as the mean ± standard
deviation (SD). (B) 225ZL cells were stimulated after starvation with IGF2 in the presence or absence of
1 µM of ceritinib. The expression of IGF1R, insulin receptor (INSR), and the phosphorylated form of
INSR (P-INSR) was analyzed by Western blot with specific antibodies. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as loading control. A representative experiment of two independent
experiments is shown.
2.7. Ceritinib Induces Tumor Regression in Vivo
Following the second relapse and in the absence of established treatment options, we switched to
a personalized therapy protocol based on our molecular analysis of the tumor and our in vitro
model (Figure 6). We decided to start with the inhibition of the SHH pathway, because the
involvement of the SHH pathway in the biology of pediatric brain tumors is well established [33].
We did not use vismodegib to target the SHH pathway, because in our in vitro model, vismodegib
reduced the cell proliferation to about 85% of the control, while the effect on the proliferation of
ATO was much more impressive (about 16% of the control). Moreover, SMO inhibition causes
permanent defects in bone structure in young mice and young children, and its use has to be carefully
considered with respect to long-term toxicities [34,35]. As a chemotherapy backbone, we incorporated
systemic VA (vincristine and actinomycin-D) and VAd (adriamycin) cycles and intraventricular (via
Ommaya) cytarabine and etoposide-Gry. Arsenic trioxide synergizes with vincristine, doxorubicin,
and etoposide [36,37]. Actinomycin-D was included to re-establish the tumor-suppressive function of
TP53 [38]. The intraventricular therapy was based on the MEMMAT protocol (NCT01356290), a Phase
II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive
medulloblastoma, that has also shown activity in different pediatric brain tumors [39].
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Figure 6. Personalized therapy protocol. Chemotherapy incorporated systemic (ctx) VA (vincristine
and actinomycin-D, red) and VAd (adriamycin, blue) blocks, and intraventricular (via Ommaya)
cytarabine (araC, yellow) and etoposide-Gry (eto, green). ATO was administered to coincide with the
chemotherapy backbone as an intravenous (iv) treatment for 1 week (bright grey), and was subsequently
switched to an oral ATO formulation (dark grey). The duration of ATO treatment lasted 68 days (9.7
weeks) in total. Ceritinib was given for 93 days. A metastatic lesion in the cerebellum was detected by
MRI after 30 days of ceritinib treatment in combination with VA and intraventricular therapy (blue star).
After 30 days of ceritinib monotherapy following the detection of the metastatic relapse, a response
to the treatment was confirmed by MRI (red star). Surgical removal of the sanguineous necrotic area
was performed (big blue arrow). A third relapse was detected by MRI (green star) two weeks after the
detection of the response. The patient died 27 months after initial diagnosis and 3.5 months after the
third relapse.
ATO was administered to coincide with the chemotherapy backbone as an intravenous (iv)
treatment for 1 week, and was subsequently switched to an oral ATO formulation [40] for a period of
approximately 10 weeks in order to forgo hospitalization of the patient. Recently, we have experienced
the clinical use of oral ATO in a pediatric brain tumor patient with BCOR alteration [28]. To reach
therapeutically efficacious concentrations, we have chosen a higher dose than recommended for the
treatment of pediatric patients with APL (0.2 mg/kg BW daily versus 0.15 mg/kg BW). ATO was initially
well tolerated intravenously and orally. At week 9, the patient complained about violent leg pain in
temporal association to the ATO administration, which was therefore interrupted. At the end of the
treatment (67 days), the concentration of ATO was of 3.5 µg/L in the cerebrospinal fluid (CSF) and 30.5
µg/L in the plasma. This concentration was far below the expected concentration based on data of
patients with APL and our own data on HGNET-BCOR [28,41], suggesting an incompliance of the
patient due to the side effects, which was confirmed by the mother at a future date.
We switched to ceritinib for approximately 3.5 months. Due to the high malignancy of the disease,
we initially decided to maintain the backbone of therapy in parallel to ceritinib for the first four weeks.
Furthermore, it was unknown if the efficacy of the ceritinib monotherapy, which was successfully
used to target ALK, was equivalent in the context of off-targeting IGF inhibition. The combination
of IGF inhibition and chemotherapy is supported by clinical data showing that the inhibition of IGF
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signaling can enhance the effects of chemotherapy [42]. The combined therapy was maintained until
the detection of the new cerebellar lesion (blue star in Figure 6). At this point, we decided to apply
ceritinib alone. The rationale was on one hand, that no further benefit was observed, and on the
other hand, that so far, no clinically proven interaction of ceritinib with chemotherapy was known.
Ceritinib has been shown to be effective as monotherapy in brain metastasis of lung cancer (with a
median time to intracranial response of 6.1 weeks [43]). Additionally, we intended to improve the
quality of life of the patient, avoiding further hospitalization. Ceritinib was applied as opened capsules,
dissolving pH-dependent (pH 4.2) in commercially available cherry–banana juice according to the
staff recommendation of the Hospital for Sick Kids, Toronto, Canada, to facilitate the intake of oral
chemotherapy in children. Due to the well-known side effects of nausea and vomiting caused by
ceritinib, the patient merely received 350 mg/m2 body surface area in preference to the recommended
without-food dosage of 510 mg/m2 body surface area in other pediatric studies (NCT01742286). Beside
nausea, no further toxicity related to the ceritinib treatment was observed, including cardiac, liver, lung,
or gastrointestinal symptoms, which were investigated weekly by ECG and blood works. After 30 days
of ceritinib monotherapy, a response to the treatment was confirmed by MRI (Figure 7). The larger
right temporal lesion developed diffuse hemorrhagic transformation under therapy with ceritinib
(Figure 7, A/B versus D/E) and was removed surgically 10 days later. Histopathology demonstrated
near complete necrosis as well as bleeding with only scattered areas of viable cells. Bleeding and
necrosis have been previously described in association with response to IGF1R inhibitors in relapsed
malignant astrocytoma and squamous non-small cell lung carcinoma [44,45]. It remains to be clarified if
an off-target inhibition by ceritinib is comparable to an inhibition with specific IGF inhibitors in term of
adverse events such as hemorrhage. Moreover, a smaller cerebellar lesion has reduced contrast uptake
within one month under therapy with ceritinib (Figure 7, C versus F, magnified images). Following the
detection of the response by MRI, the patient refused the periodic intake of ceritinib, and post-surgical
MRI revealed a third relapse 14 days after the detection of the response. The patient died 27 months
after initial diagnosis and 3.5 months after the third relapse.
Figure 7. The target lesion is sensitive to the targeted therapy with ceritinib. MRI before therapy
with ceritinib (A–C) showing a right sided solid mesiotemporal tumor (A, white arrow) with a cystic
component, as well as a contrast media enriching metastatic lesion within the cerebellar folia (C, FLAIR
post-contrast media, white arrow head). After 30 days of ceritinib (D–F), the metastatic lesion was
regredient (F, FLAIR post-contrast media, white arrow head), and hemorrhagic transformation (E, T2*,
black arrow) of the tumor was detected.
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2.8. Ceritinib Penetrates the Human Brain
To assess the concentration of ceritinib, we developed and validated an UPLC/MS/MS-based
assay. The patient’s plasma concentrations reached a peak of 1.70 µM after 46 days (the concentration
described in the literature is ~1 µM [8]). This peak plasma level of ceritinib was observed at time point
d 12 before MRI response was detected. Following the detection of the response, the patient refused
the periodic intake of the medication, and the plasma level decreased until 0.9 µM. The post-surgical
third relapse followed approximately 2 weeks of markedly diminished ceritinib levels. Interestingly,
no ceritinib (< 2.5 ng/mL) was detectable in the CSF samples that were collected in parallel to the
plasma samples. However, after the surgical removal of the sanguineous necrotic area, we quantified a
ceritinib concentration of 1516 ng/g (2.72 µM) in the isolated tumor areal, while the concentration of
ceritinib in the plasma was 0.9 µM one day before the surgery. These results indicated that ceritinib
was able to cross the blood–brain barrier (BBB) and reached effective concentrations in the tumor.
3. Discussion
Numerous challenges remain in the development of molecularly targeted therapies, including
the identification of meaningful targets, delivery of agents at the target site, and the determination of
response to these agents. This is particular true for pediatric patients in whom underlying germline
mutations can contribute to unusual histologies. The percentage of brain cancer in children and
adolescents attributable to an underlying genetic syndrome or inherited susceptibility is estimated
at 8.6% [46]. Germline mutations in NOTCH1 cause aortic valve disease [47] and have been found
to cause Adams-Oliver syndrome [48]. All these alterations are associated with a downregulation of
the Notch signaling, while in our patient, the Notch signaling was upregulated. To our knowledge,
NOTCH1 germline mutations have not been associated with cancer so far. However, somatic NOTCH1
mutations have been described in hematopoietic and solid tumors [49–51]. Notably, the Notch pathway
is implicated in ependymoma oncogenesis [52], and NOTCH1 mutations have been described to present
in 8.3% of pediatric ependymomas samples in one study [53]. The mutation described here is localized
in the EGF-like domain of NOTCH1, which protects NOTCH1 from proteolytic cleavage inhibiting
uncontrolled constitutive activation, and governs ligand-induced homodimerization [54]. It remains to
be clarified if this mutation was the driver element for the activation of the Notch pathway in the tumor
of the patient described in this work. As an alternative, the Notch pathway could also be indirectly
activated via the WNT pathway [55]. The germline NOTCH1 mutation was accompanied by a somatic
TP53-inactivating mutation. Notably, Notch1 expression results in SHH medulloblastoma formation
in p53-deficient mice [56], suggesting a synergistic effect of both mutations in the malignancy of the
disease, and a possible cross-talk between the Notch and SHH pathways in the patient’s tumor.
Developmental pathways, such as those regulated by IGF, Hedgehog, WNT, and Notch, play key
roles in the controls of cell fate decisions during development. A cross-talk among these signaling
pathways is typical for cancer stem cells, and targeting embryonic signaling pathways is a current
challenge in cancer therapy [57]. In brain tumors, IGF1R is frequently activated in medulloblastoma [3],
and INSR and IGF1R are frequently activated in glioblastoma [5]. To date, neither monoclonal
antibodies nor small molecule tyrosine kinase inhibitors directed against the IGF pathway have been
approved. Ceritinib inhibits kinases such as ROS proto-oncogene 1 (ROS1), INSR, and IGF1R, although
it is most active against ALK [9]. Lung cancer patients with brain metastases also respond to the
treatment with ceritinib, suggesting that this drug is effective across the BBB [58]. The concentration
achieved in the mouse brain after oral administration is low, with a brain-to-plasma ratio below 0.3 [59],
but the blood-to-brain exposure ratio of ceritinib in humans is yet to be determined. We were not able
to detect ceritinib in the CSF; however, we detected a high concentration in the tumor, suggesting
that ceritinib crosses the BBB and is actively transported to the tumor. Ceritinib is a substrate of the
eﬄux transport protein P-gp, which is in discussion to be an effective resistance mechanism against
ceritinib [60], and which is located in the BBB [61]. From this point of view, low ceritinib brain
concentration appears to be a reasonable consequence. However, the results in this patient reveal about
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doubled ceritinib tumor concentration compared to plasma, although ceritinib was not detectable
in the CSF. Leakiness of the BBB has been described, particularly in patients with a WNT-activated
brain tumor, and this could explain the effective penetration of ceritinib in the brain in this patient [62].
The accumulation in the tumor rather than in the CSF may be explained by a parallel efficient uptake
transport, although it is reported, that ceritinib is not a substrate of breast cancer resistance protein
(BCRP), organic cation transporter 1 (OCT1), organic anion transporter 2 (OAT2), or organic anion
transporting polypeptide 1 (OATP1) [63]. Therefore, the specific and irreversible binding of ceritinib to
so-far unknown intracellular binding sites in the tumor seems to be the most reasonable explanation.
After a first response to ceritinib, the tumor progressed. Although we cannot rule out whether the
reduced intake of ceritinib by the patient after detection of the response may have contributed to the
progress, it is already known that several mechanisms are associated with the resistance to IGF pathway
inhibition. These mechanisms include the compensatory actions of other growth factor receptors [30].
In the tumor of the patient described in this work, other embryonic pathways were upregulated, and it
is possible that the tumor cells switched to other signaling to overcome INSR blockade. During the
course of disease, the tumor displayed rapid clonal evolution, so that a selection of resistant cell clones
is likely. The identification of distinctive mechanisms of resistance in this particular patient is ongoing.
In conclusion, here we present the targeting of the IGF receptor INSR using ceritinib in a patient with
an incurable neuroepithelial brain tumor. Due to the limitations of our work, which included only
one patient with an unknown histology; a systematic investigation of ceritinib for the treatment of
IGF-driven tumors in the framework of a clinical study is imperative.
4. Materials and Methods
4.1. Tissue Samples and Cells
Fresh tumor material from the first relapse (no. 225) was obtained during standard surgery.
The RNA of normal brain tissues (adult frontal lobe no. 110 and adult parietal lobe no. 111) was
sourced from commercial vendors (Biocat, Heidelberg, Germany). For the isolation of a primary cell
culture (225ZL), the fresh tumor sample (no. 225) was disrupted with the GentleMACS Dissociator
(Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany), and the cells were dissociated with 0.25%
trypsin. The cells were cultured in DMEM medium containing 10% human serum, 1% l-glutamine,
and 1% penicillin-streptomycin (all Sigma-Aldrich, Taufkirchen, Germany). Cell at passage 5 were used
for further experiments. This study has been performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later amendments. The parents gave their informed
consent prior to their inclusion in the study. Formal approval of the local ethics committee for this
study was not required, as this was a single case investigation. For details about the ethics, see the
supplemental material and methods.
4.2. Nucleic Acid Extraction
Tumor samples were analyzed by a pathologist, and regions containing vital tumors were isolated
for further processing. DNA from blood and tissues was extracted using a Gentra Puregene Blood
Kit (Qiagen, Hilden, Germany). RNA isolation was conducted using the RNeasy Lipid Tissue Mini
Kit (Qiagen). RNA was converted to cDNA by using PrimeScript RT Reagent Kit with gDNA
Eraser (Takara Bio Europe, Saint-Germain-en-Laye, France). Quality control was performed using a
Bioanalyzer2100 (Agilent Technologies, Waldbronn, Germany). Only RNAs with a RIN value > 7 were
used for RNA sequencing analysis and qRT-PCR.
4.3. DNA Sequencing
PCR products were sequenced using an ABI Prism 3100 Genetic Analyzer and the BigDye
v3 Terminator Kit (Thermo Fisher, Dreieich, Germany). The sequences were compared
to the reference sequence using the Sequencher program (Gene Codes, Corp., Ann Arbor,
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MI, USA). The following primers were used: NOTCH1: 5′- GATGTCAACGAGTGTGGCCA
and 5′- AGTTCCGGGAAACTCCAGAGA; TP53: 5′- GCTTGCCACAGGTCTCCC and
5′- GAGGCAAGCAGAGGCTGG.
4.4. qRT-PCR
qRT-PCR was performed using the Light Cycler 480 II detection system and software (Applied
Biosystems, Darmstadt, Germany) with a KAPA SYBR FAST Light Cycler 480 Kit (PeqLab, Erlangen,
Germany). The following primers were used: AXIN2: 5′-GCTCAGAGCTTGACCCTGG
and 5′- TCATACATCGGGAGCACCGT; HPRT1: 5′-TGACACTGGCAAAACAATGCA
and 5′-GGTCCTTTTCACCAGCAAGCT. GLI2: 5′-TCCACACACGCGGAACACCA
and 5′- CAGCTGGCTCAGCATGGTCA, HES4: 5′-GTGCAGGTGACGGCCGC and
5′- CGGCCAGGAAGCGGTTCA.
4.5. RNA Sequencing
Libraries were constructed using the TruSeq mRNA stranded protocol (Illumina, San Diego, CA,
USA) using 2 µg of total RNA. Pair-end sequencing with a read length of 150 bps was performed on a
NextSeq500 Instrument (Illumina, San Diego, CA, USA). A total of 50 million reads per library were
produced. Read mapping was performed using the TopHat2 v2.0.7 aligner [64] and the Homo sapiens
UCSC hg19 reference genome (RefSeq gene annotations). The FPKM values of reference genes and
transcripts were estimated by Cuﬄinks 2.0.5 [65]. TPM values of genes and transcripts were calculated
according to Lior Pachter (https://arxiv.org/abs/1104.3889). Ingenuity pathway analysis (IPA; Ingenuity
Systems/Qiagen, Redwood City, CA, USA) was used to map lists of significant genes to biological
pathways. To identify mutations, data were processed using BWA Enrichment v1.0 for the generation
of BAM files and GATK for variant calling. Translocation was identified with TopHat-Fusions [66].
Analysis of variants was performed with the VariantStudio software (Illumina, San Diego, CA, USA).
4.6. Methylation Analysis and Copy Number Variation Profiles
DNA methylation analyses were performed using an EPIC 850k DNA methylome bead array
(Illumina, San Diego, CA, USA). We used standard protocols for tissue and DNA processing.
Hybridization and processing of the chip was performed as indicated by the manufacturer. Data were
preprocessed using Illumina Genome Studio; further analysis was performed after uploading raw data
(idat files) onto the platform MolecularNeuroPathology.org 2018 version 3.1.2, which provides brain
tumor classifier results (version v11b4) and copy number variation profiles. Furthermore, we compared
the DNA methylation profiles of the unclassified tumor specimens with tumor tissue deriving from
common childhood brain tumor entities by applying principal component analysis using the R package
“RnBeads” [67].
4.7. Cellular Proliferation Assays
Linsitinib, vismodegib, and ceritinib (Selleck Chemicals, Houston, TX, USA) were dissolved in
DMSO (Sigma-Aldrich, Taufkirchen, Germany) to a final concentration of 10 mM. Arsenic trioxide
(ATO) was prepared as previously described [68]. 225ZL cells were plated in triplicates at a density of
5000 cells/well in a 96-well plate, and incubated with the different drugs. Viable cells were quantified
using the cell proliferation reagent WST-1 (Roche, Mannheim, Germany).
4.8. Phosphorylation Assay
225ZL cells were grown in charcoal-stripped (Sigma-Aldrich, Taufkirchen, Germany) DMEM
supplemented with 10% human serum, 2 mM of L-Glutamine, 1 mM of sodium pyruvate,
and penicillin–streptomycin for 1 day. The cells were serum-starved for 24 h, and then treated
with 1 µM of ceritinib for two hours, followed by incubation with 20 ng/mL of IGF2 for 15 min. Cell
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lysates were loaded on SDS-PAGE gels, followed by blotting to a polyvinylidene difluoride membrane
(BioRad Laboratories, Inc., Hercules, CA, USA). The following antibodies were obtained from Cell
Signaling Technology (Cambridge, UK): GAPDH (14C10) (cat # 2118, 1:1000 dilution), IGF1 receptor β
(D23H3) XP® (cat # 9750, 1:1000 dilution) and phospho-IGF1 receptor β (Tyr1131)/Insulin Receptor β
(Tyr1146) (cat # 3021, 1:1000 dilution). Detection was done by a SuperSignal™ West Dura Extended
Duration Substrate (Thermo Fisher Scientific, Waltham, MA, USA), and the imaging was performed on
Fusion Pulse TS (Vilber Lourmat, Eberhardzell, Germany).
4.9. Targeted Therapy Protocol
The patient was enrolled for genomic profiling following the parent’s informed consent. Tumor
and blood samples were then acquired, processed, molecularly profiled, and analyzed computationally.
Molecular results were reviewed in the in-house pediatric tumor board. No early-phase clinical trial
was available for this patient. The parents have been informed of all the disease and treatment-related
relevant molecular results. Targeted therapy was initiated following parent’s consent regarding
compassionate and off-label use. For protocol details, see the results section.
4.10. Arsenic Concentration
The total arsenic concentration in CSF and plasma was analyzed as described in [28].
4.11. Ceritinib Quantification
Ceritinib concentration in plasma, CSF, and tumor tissue was quantified using UPLC-MS/MS-
and liquid/liquid extraction techniques. For quantification in the tumor tissue, regions containing
vital tumors were isolated from the surrounding necrotic regions by a pathologist. The plasma, CSF,
and tissue samples were spiked with internal standards d7-ceritinib and boric buffer pH 9 (50 µL).
Subsequently tert-butylmethylether was added, shaken for 10 min, and centrifuged (10 min, 3000 g).
The supernatants were evaporated to dryness in a stream of nitrogen at 40 ◦C, reconstituted by adding
LC eluent (100 µL), and injected (20 µL) into the UPLC-MS/MS system, which consisted of an Acquity
sample manager, an Acquity solvent manager, and a TQD triple stage quadrupole mass spectrometer
(Waters GmbH, Eschborn, Germany). For chromatographic separation, an Acquity CSH C18 (1.7 µm;
2.1 × 50 mm) column (Waters GmbH, Eschborn, Germany) at 40 ◦C was used. The eluent consisted of
water, including 0.01% formic and 5% acetonitrile (A) and acetonitrile including 0.01% formic acid
(B). For separation a gradient program at 0.5 mL/min was applied. From 0 to 0.5 min, 95% A/5% B
was used. From 0.5 to 2.5 min, the ratio was linearly changed to 5% A/95% B and held for 3.5 min.
The eluent was introduced directly into the electrospray ion source of the tandem mass spectrometer
(MS/MS). The MS/MS transitions monitored in the positive ion mode were m/z 558.1→m/z 84.0 at 38
V for ceritinib and m/z 565.1→m/z 84.0 at 38 V for d7-ceritinib. The assay was validated according
to common FDA and European Medicines Agency (EMA) validation guidelines on bioanalytical
method validation. The lower limit of quantification of ceritinib was 2.5 ng/mL. The calibrated range
was 2.5–1000 ng/mL (4.5–1790 nM) with correlation coefficients > 0.995. The overall accuracy varied
between –2.3% and +5.2%, and an overall precision ranging from 2.3% to 12.4%.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/17/
4267/s1.
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Abbreviations
Act-D dactinomycin/ actinomycin-D
araC cytarabine
ATO arsenic trioxide
BBB Blood-brain barrier
BCC basal cell carcinoma
CSF cerebrospinal fluid
Eto etoposide
HGNET-BCOR High grade neuroepithelial tumor with BCOR alteration
IGF insulin-like growth factor
IPA Ingenuity Pathway Analysis
iv intravenous
MRI magnetic resonance imaging
RNA seq whole-transcriptome sequencing
ROS1 proto-oncogene receptor tyrosine kinase
SHH sonic hedgehog
TPM transcripts per kilobase million
VCR vincristine
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